CN1324033C - 噻吩并[2,3－d]嘧啶二酮及其在自身免疫性疾病调节中的用途 - Google Patents

噻吩并[2,3－d]嘧啶二酮及其在自身免疫性疾病调节中的用途 Download PDF

Info

Publication number
CN1324033C
CN1324033C CNB028152506A CN02815250A CN1324033C CN 1324033 C CN1324033 C CN 1324033C CN B028152506 A CNB028152506 A CN B028152506A CN 02815250 A CN02815250 A CN 02815250A CN 1324033 C CN1324033 C CN 1324033C
Authority
CN
China
Prior art keywords
methyl
pyrimidine
hydroxyl
thieno
different
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028152506A
Other languages
English (en)
Chinese (zh)
Other versions
CN1538970A (zh
Inventor
雷切尔·H·雷诺兹
安东尼·H·英戈尔
鲁克萨纳·T·拉苏尔
西蒙·D·吉尔
马丁·E·库珀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1538970A publication Critical patent/CN1538970A/zh
Application granted granted Critical
Publication of CN1324033C publication Critical patent/CN1324033C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
CNB028152506A 2001-07-28 2002-07-24 噻吩并[2,3－d]嘧啶二酮及其在自身免疫性疾病调节中的用途 Expired - Fee Related CN1324033C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0118479.5A GB0118479D0 (en) 2001-07-28 2001-07-28 Novel compounds
GB0118479.5 2001-07-28

Publications (2)

Publication Number Publication Date
CN1538970A CN1538970A (zh) 2004-10-20
CN1324033C true CN1324033C (zh) 2007-07-04

Family

ID=9919407

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028152506A Expired - Fee Related CN1324033C (zh) 2001-07-28 2002-07-24 噻吩并[2,3－d]嘧啶二酮及其在自身免疫性疾病调节中的用途

Country Status (25)

Country Link
US (2) US7384950B2 (no)
EP (1) EP1414825B9 (no)
JP (1) JP4456364B2 (no)
KR (1) KR100897469B1 (no)
CN (1) CN1324033C (no)
AR (1) AR038000A1 (no)
AT (1) ATE374204T1 (no)
AU (1) AU2002319469B2 (no)
BR (1) BR0211262A (no)
CA (1) CA2453274A1 (no)
DE (1) DE60222671T2 (no)
ES (1) ES2292784T3 (no)
GB (1) GB0118479D0 (no)
HK (1) HK1065785A1 (no)
HU (1) HUP0402336A3 (no)
IL (2) IL159785A0 (no)
IS (1) IS2598B (no)
MX (1) MXPA04000677A (no)
MY (1) MY138145A (no)
NO (1) NO328713B1 (no)
NZ (1) NZ530495A (no)
PL (1) PL211351B1 (no)
RU (1) RU2294937C9 (no)
WO (1) WO2003011868A1 (no)
ZA (1) ZA200400574B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801399D0 (sv) 1998-04-21 1998-04-21 Astra Pharma Prod Method and apparatus for filling containers
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
WO2004013141A1 (en) 2002-08-06 2004-02-12 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004065395A1 (en) * 2003-01-17 2004-08-05 Astrazeneca Ab Thienopyridazinones and their use in modulation of autoimmune disease
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004080463A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
AU2004308299B2 (en) 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006023440A2 (en) * 2004-08-18 2006-03-02 Merck & Co., Inc. Mitotic kinesin inhibitors
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
ATE518860T1 (de) 2005-06-22 2011-08-15 Plexxikon Inc Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
RU2341527C1 (ru) * 2007-07-17 2008-12-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные азагетероциклы, включающие пиримидиновый фрагмент, способ их получения и ингибиторы pi3k киназ
RU2345996C1 (ru) * 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
CA2711713A1 (en) * 2008-01-22 2009-07-30 Boehringer Ingelheim International Gmbh Substituted amino-benzimidazoles, medicaments comprising said compound, their use and their method of manufacture
BRPI1013705A2 (pt) * 2009-03-23 2016-04-05 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
TWI404719B (zh) 2009-04-03 2013-08-11 Hoffmann La Roche 組合物及其用途
US20110112127A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
EP2672967B1 (en) 2011-02-07 2018-10-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
JP5990980B2 (ja) * 2012-04-02 2016-09-14 大日本印刷株式会社 オランザピンの中間体の製造方法
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264382A (zh) * 1997-05-28 2000-08-23 英国阿斯特拉药品有限公司 新的化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469014B1 (en) * 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
EE200000318A (et) 1997-12-05 2001-08-15 Astrazeneca Uk Limited Uudsed ühendid
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
NZ509809A (en) * 1998-08-28 2002-11-26 Astrazeneca Ab Thienol[2,3-d]pyrimidinediones which exhibit immunosuppressive activity
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2004065395A1 (en) 2003-01-17 2004-08-05 Astrazeneca Ab Thienopyridazinones and their use in modulation of autoimmune disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1264382A (zh) * 1997-05-28 2000-08-23 英国阿斯特拉药品有限公司 新的化合物

Also Published As

Publication number Publication date
ES2292784T3 (es) 2008-03-16
GB0118479D0 (en) 2001-09-19
AU2002319469B8 (en) 2003-02-17
IL159785A0 (en) 2004-06-20
MXPA04000677A (es) 2004-04-05
HK1065785A1 (en) 2005-03-04
EP1414825B9 (en) 2009-09-16
US20080207642A1 (en) 2008-08-28
JP2004538316A (ja) 2004-12-24
DE60222671D1 (de) 2007-11-08
CA2453274A1 (en) 2003-02-13
WO2003011868A1 (en) 2003-02-13
DE60222671T2 (de) 2008-06-26
NO20040364L (no) 2004-03-29
NO328713B1 (no) 2010-05-03
PL211351B1 (pl) 2012-05-31
RU2294937C2 (ru) 2007-03-10
PL369232A1 (en) 2005-04-18
HUP0402336A2 (hu) 2005-02-28
US20040254198A1 (en) 2004-12-16
NZ530495A (en) 2005-07-29
AR038000A1 (es) 2004-12-22
KR100897469B1 (ko) 2009-05-14
AU2002319469B2 (en) 2007-08-09
HUP0402336A3 (en) 2008-09-29
IL159785A (en) 2009-11-18
RU2294937C9 (ru) 2007-07-20
EP1414825B1 (en) 2007-09-26
ZA200400574B (en) 2005-04-26
CN1538970A (zh) 2004-10-20
IS7118A (is) 2004-01-19
US7384950B2 (en) 2008-06-10
IS2598B (is) 2010-03-15
JP4456364B2 (ja) 2010-04-28
MY138145A (en) 2009-04-30
BR0211262A (pt) 2004-07-20
EP1414825A1 (en) 2004-05-06
KR20040017355A (ko) 2004-02-26
RU2004102392A (ru) 2005-07-10
ATE374204T1 (de) 2007-10-15

Similar Documents

Publication Publication Date Title
CN1324033C (zh) 噻吩并[2,3－d]嘧啶二酮及其在自身免疫性疾病调节中的用途
CN1264825C (zh) 用作mGluR2拮抗剂Ⅱ的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物
CN1178938C (zh) 1,2-稠合的喹啉衍生物
CN1031570C (zh) 吡唑并吡啶化合物的制备方法
CN1269813C (zh) 作为细胞增生抑制剂的咪唑－5－基－2－苯胺基－嘧啶
CN100343238C (zh) 用作抗肿瘤药物的喹唑啉衍生物
CN1045769C (zh) 新颖的咪唑亚硫衍生物的制备方法
CN1761672A (zh) 噻吩并嘧啶二酮及其在调节自身免疫疾病中的用途
CN1268626C (zh) 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物
CN1993349A (zh) 作为erbb受体酪氨酸激酶的喹唑啉衍生物
CN1863779A (zh) 新型吲唑衍生物
CN1897936A (zh) 环状胍、含有这种化合物的组合物及其使用方法
CN1527710A (zh) 作为促肾上腺皮质激素释放因子配体的取代的吡嗪酮、吡啶和嘧啶
CN1639165A (zh) 作为激酶抑制剂的嘌呤衍生物
CN1993359A (zh) 杂环取代的环状脲衍生物、其制备及其作为激酶抑制剂的药物用途
CN1931859A (zh) 新的稠合咪唑衍生物
CN1960984A (zh) 作为mglu5受体拮抗剂的吡啶－4－基－乙炔基－咪唑和吡唑
CN1514833A (zh) 新型酪氨酸激酶抑制剂
CN1934094A (zh) 二芳基取代杂环5元环衍生物
CN1882572A (zh) 作为抗肿瘤药物的喹唑啉衍生物
CN1152877C (zh) 哌嗪衍生物
CN1681508A (zh) 新型激酶抑制剂
CN1542010A (zh) 吡咯并三嗪和嘧啶化合物
CN1768054A (zh) 环状脲衍生物、其制备方法以及作为激酶抑制剂的药物用途
CN1139928A (zh) 新化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070704

Termination date: 20120724